Establishes patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurer-designated pharmacy; prohibits certain "brown bagging" and "white bagging" policies regarding pharmacy provided medications.
S05314 would amend New York’s insurance law and public health law to restrict certain insurer and health plan pharmacy distribution practices for patient-specific medications administered in a physician’s office, hospital, or clinic. The bill prohibits insurers and health plans from requiring a designated pharmacy to dispense medication directly to a patient when the patient is expected to transport it for administration at a provider site, a practice commonly referred to as “brown bagging.” It also limits “white bagging” arrangements by barring plans from requiring provider-administered drugs to be shipped from a designated pharmacy unless the insurer or plan enters into a detailed agreement with the receiving provider.
Under that agreement, the insurer or plan would have to meet a series of patient-safety and logistics conditions, including 90 days’ notice before implementation, an expedited exception process when a provider says the arrangement is unsafe, same-day delivery, 24/7 pharmacist or nurse access, cold-chain handling, pedigree documentation, accreditation, clinically appropriate ready-to-administer dosage forms, and site-neutral payment that covers provider handling, storage, and disposal costs. The bill also bars these arrangements for drugs requiring sterile compounding by the provider or drugs whose dose must be determined from same-day lab or test results. It applies these rules across commercial insurers, health care corporations, and health care plans, and takes effect immediately.
The bill would add new restrictions and operational requirements to sections of the Insurance Law and Public Health Law governing insurers, health care corporations, and health care plans in New York. It would limit the ability of plans to mandate patient transport of medications and would condition any insurer-designated pharmacy distribution for provider-administered drugs on specific safety, notice, delivery, and payment standards. Affected parties would include insurers, pharmacy benefit arrangements, designated pharmacies, physicians, hospitals, clinics, and patients receiving infused or otherwise provider-administered medications.
Based on the bill text and caption, the measure appears to be framed as a patient-safety and quality-assurance bill, suggesting generally supportive intent toward providers and patients concerned about medication handling. The caption’s reference to prohibiting “brown bagging” and “white bagging” indicates the bill is aimed at practices that have drawn criticism in the health care sector. No committee transcript or vote data was provided, so there is no recorded legislative debate or roll-call sentiment to assess beyond the bill’s protective framing.
The main point of contention is likely the balance between patient safety and insurer cost-control or pharmacy benefit management practices. Supporters would likely emphasize risks from improper handling, temperature control, delayed delivery, and provider inability to verify medication pedigree, especially for infused drugs and other high-risk therapies. Opponents or affected insurers may object to the administrative burden, added costs, site-neutral payment requirements, and limits on utilization management tools, particularly where the bill restricts mandatory use of designated pharmacies and excludes certain same-day lab-dependent or sterile-compounding medications from these arrangements.